Status:

RECRUITING

Botulinum Neurotoxin for Children With CP: a Delicate Balance Between Clinical Benefits and Muscular Harm

Lead Sponsor:

Universitaire Ziekenhuizen KU Leuven

Conditions:

Spastic Cerebral Palsy (sCP)

Eligibility:

All Genders

2-16 years

Brief Summary

A cross-sectional design study will be carried out to explore the morphological muscle properties and alterations in muscle composition on a macroscopic level in children with spastic cerebral palsy (...

Detailed Description

Background: Altered muscle composition, including increased fat infiltration and collagen content, is a key factor in impaired muscle function in cerebral palsy (CP). However, quantitative data on mus...

Eligibility Criteria

Inclusion

  • \- Children with spastic cerebral palsy
  • Inclusion criteria:
  • Children (boys/girls) with congenital brain lesion, confirmed with neuro-imaging such as MRI
  • At high-risk for CP or diagnosed spastic type of CP
  • (Suspected) Gross Motor Function Classification Scale (GMFCS) Level I-III
  • Uni or bilateral involvement
  • Aged between 2-16 years
  • Exclusion criteria:
  • Presence of dyskinesia or ataxia
  • Severe co-morbidities (cognitive problems)
  • BTX treatment in past 10 months
  • Previous surgery less than 6 months at the investigated muscles.
  • Previous orthopedic or neurosurgery
  • Severe ankle deformities
  • Weight for height values \>2SD from mean
  • Typically developing children
  • Inclusion criteria:
  • • Aged between 2-16 years
  • Exclusion criteria:
  • History of neurological, orthopedic or muscular problems
  • Involvement in an elite or high-performance sporting program (Children performing the same sports for \> 5 hours/week will be excluded)

Exclusion

    Key Trial Info

    Start Date :

    February 3 2025

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2028

    Estimated Enrollment :

    51 Patients enrolled

    Trial Details

    Trial ID

    NCT06991725

    Start Date

    February 3 2025

    End Date

    December 1 2028

    Last Update

    June 2 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    UZ Leuven

    Leuven, Vlaams-Brabant, Belgium, 3000

    Botulinum Neurotoxin for Children With CP: a Delicate Balance Between Clinical Benefits and Muscular Harm | DecenTrialz